

Peptide Arrays, Peptides for Expected Conserved MHC Class I Epitopes of Influenza Virus A Proteins

Catalog No. NR-2667

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

Lot P525217A: New England Peptide, LLC
Lot PB0623: CS Bio Company Inc.

Product Description:

NR-2667 contains eight peptide arrays which consist of expected conserved Major Histocompatibility Complex (MHC) Class I epitopes of influenza A virus proteins M1 (NRC-248; 21 peptides), M2 (NRC-249; 5 peptides), NA (NRC-250; 3 peptides), NP (NRC-251; 19 peptides), NS2 (NRC-252; 2 peptides), PA (NRC-253; 28 peptides), PB1 (NRC-254; 51 peptides) and PB2 (NRC-255; 30 peptides).¹ Peptides are 9-mers. Please see Table 1 for sequence of individual peptides.

Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2). Peptides can almost always be dissolved in 100% DMSO.

Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water or 1 mL of 100% DMSO. The DMSO can be slowly diluted to a lower concentration with aqueous medium. Care must be taken to ensure that the

peptide does not begin to precipitate out of solution. For cell-based assays, 0.5% DMSO in medium is usually well-tolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution (see Table 2). These solvents may not be appropriate for certain applications, including cell-based assays.

Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5–6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Arrays, Peptides for Expected Conserved MHC Class I Epitopes of Influenza Virus A Proteins, NR-2667."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

Product Information Sheet for NR-2667

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals

contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

1. Epstein, S. L., et al. "Cell-Mediated Immunity to Influenza." *Textbook of Influenza*. Eds. Nicholson, K., et al. London: Blackwell Science; 1998. Chapter 24.

ATCC® is a trademark of the American Type Culture Collection.



| Table 1 | | |
|--|--------|-------------------|
| Peptide | Length | Sequence |
| NRC-248: Influenza Virus A, M1 Peptides | | |
| 1 of 21 | 9 | 29-EDVFAGKNT-37 |
| 2 of 21 | 9 | 31-VFAGKNTDL-39 |
| 3 of 21 | 9 | 37-TDLEALMEW-45 |
| 4 of 21 | 9 | 49-RPILSPLTK-57 |
| 5 of 21 | 9 | 51-ILSPLTKGI-59 |
| 6 of 21 | 9 | 56-TKGILGFVF-64 |
| 7 of 21 | 9 | 58-GILGFVFTL-66 |
| 8 of 21 | 9 | 60-LGFVFTLTV-68 |
| 9 of 21 | 9 | 66-LTVPSERGL-74 |
| 10 of 21 | 9 | 68-VPSEGLQR-76 |
| 11 of 21 | 9 | 71-ERGLQRRRF-79 |
| 12 of 21 | 9 | 75-QRRRFVQNA-83 |
| 13 of 21 | 9 | 76-QRRRFVQNAL-84 |
| 14 of 21 | 9 | 122-GALASCMGL-130 |
| 15 of 21 | 9 | 123-ALASCMGLI-131 |
| 16 of 21 | 9 | 124-LASCMGLIY-132 |
| 17 of 21 | 9 | 126-SCMGLIYNR-134 |
| 18 of 21 | 9 | 177-NRMVLASTT-185 |
| 19 of 21 | 9 | 179-MVLASTTAK-187 |
| 20 of 21 | 9 | 180-VLASTTAKA-188 |
| 21 of 21 | 9 | 181-LASTTAKAM-189 |
| NRC-249: Influenza Virus A, M2 Peptides | | |
| 1 of 5 | 9 | 30-ASIIGILHL-38 |
| 2 of 5 | 9 | 31-SIIGILHLI-39 |
| 3 of 5 | 9 | 34-GILHLILWI-42 |
| 4 of 5 | 9 | 40-LWILDRLFF-48 |
| 5 of 5 | 9 | 41-WILDRLFFK-49 |

| Peptide | Length | Sequence |
|---|--------|--------------------|
| NRC-250: Influenza Virus A, NA Peptides | | |
| 1 of 3 | 9 | 100-FSKDNSIRL-108 |
| 2 of 3 | 9 | 106-IRLSAGGDI-114 |
| 3 of 3 | 9 | 107-RLSAGGDIW-115 |
| NRC-251: Influenza Virus A, NP Peptides | | |
| 1 of 19 | 9 | 88-DPKKTGGPI-96 |
| 2 of 19 | 9 | 89-PKKTGGPIY-97 |
| 3 of 19 | 9 | 147-TYQRTRALV-155 |
| 4 of 19 | 9 | 149-QRTRALVRT-157 |
| 5 of 19 | 9 | 158-GMDPRMCSL-166 |
| 6 of 19 | 9 | 164-CSLMQGSTL-172 |
| 7 of 19 | 9 | 166-LMQGSTLPR-174 |
| 8 of 19 | 9 | 218-AYERMCNIL-226 |
| 9 of 19 | 9 | 225-ILKGKFQTA-233 |
| 10 of 19 | 9 | 226-LKGKFQTAA-234 |
| 11 of 19 | 9 | 245-SRNPNGNAEI-253 |
| 12 of 19 | 9 | 250-NAEIEDLIF-258 |
| 13 of 19 | 9 | 256-LIFLARSAL-264 |
| 14 of 19 | 9 | 257-IFLARSALI-265 |
| 15 of 19 | 9 | 258-FLARSALIL-266 |
| 16 of 19 | 9 | 296-YSLVGIDPF-304 |
| 17 of 19 | 9 | 462-GVFELSDEK-470 |
| 18 of 19 | 9 | 463-VFELSDEKA-471 |
| 19 of 19 | 9 | 464-FELSDEKAT-472 |
| NRC-252: Influenza Virus A, NS2 Peptides | | |
| 1 of 2 | 9 | 4-NTVSSFQDI-12 |
| 2 of 2 | 9 | 72-KFEEIRWLI-80 |
| NRC-253: Influenza Virus A, PA Peptides | | |
| 1 of 28 | 9 | 71-LLKHRFEII-79 |
| 2 of 28 | 9 | 74-HRFEIIIEGR-82 |
| 3 of 28 | 9 | 130-YYLEKANKI-138 |
| 4 of 28 | 9 | 131-YLEKANKIK-139 |
| 5 of 28 | 9 | 162-TLDEESRAR-170 |
| 6 of 28 | 9 | 163-LDEESRARI-171 |
| 7 of 28 | 9 | 164-DEESRARIK-172 |
| 8 of 28 | 9 | 166-ESRARIKTR-174 |
| 9 of 28 | 9 | 167-SRARIKTRL-175 |
| 10 of 28 | 9 | 245-KLSQMSKEV-253 |
| 11 of 28 | 9 | 294-DPSHEGEGI-302 |
| 12 of 28 | 9 | 296-SHEGEGEIP-304 |
| 13 of 28 | 9 | 483-IPMISKCRT-491 |
| 14 of 28 | 9 | 484-PMISKCR TK-492 |
| 15 of 28 | 9 | 507-GRSHLRNDT-515 |
| 16 of 28 | 9 | 510-HLRNDTDVV-518 |

| Table 1 | | |
|---|--------|-------------------|
| Peptide | Length | Sequence |
| 17 of 28 | 9 | 632-SIGKVCRTL-640 |
| 18 of 28 | 9 | 635-KVCRTLLAK-643 |
| 19 of 28 | 9 | 637-CRTLLAKSV-645 |
| 20 of 28 | 9 | 641-LAKSVFNSL-649 |
| 21 of 28 | 9 | 642-AKSVFNSLY-650 |
| 22 of 28 | 9 | 652-SPQLEGFSA-660 |
| 23 of 28 | 9 | 656-EGFSAESRK-664 |
| 24 of 28 | 9 | 657-GFSAESRKL-665 |
| 25 of 28 | 9 | 658-FSAESRKLL-666 |
| 26 of 28 | 9 | 659-SAESRKLLL-667 |
| 27 of 28 | 9 | 691-EECLINDPW-699 |
| 28 of 28 | 9 | 694-LINDPWVLL-702 |
| NRC-254: Influenza Virus A, PB1 Peptides | | |
| 1 of 51 | 9 | 4-NPTLLFLKV-12 |
| 2 of 51 | 9 | 16-NAISTTFPY-24 |
| 3 of 51 | 9 | 22-FPYTGDPY-30 |
| 4 of 51 | 9 | 30-YSHGTGTGY-38 |
| 5 of 51 | 9 | 77-NEPSGYAQT-85 |
| 6 of 51 | 9 | 81-GYAQTDCVL-89 |
| 7 of 51 | 9 | 83-AQTDCVLEA-91 |
| 8 of 51 | 9 | 123-TQGRQTYDW-131 |
| 9 of 51 | 9 | 127-QTYDWTLNR-135 |
| 10 of 51 | 9 | 221-ALTLNTMTK-229 |
| 11 of 51 | 9 | 228-TKDAERGKL-236 |
| 12 of 51 | 9 | 230-DAERGKLKR-238 |
| 13 of 51 | 9 | 233-RGKLKRRAI-241 |
| 14 of 51 | 9 | 235-KLKRRAIAT-243 |
| 15 of 51 | 9 | 238-RRAIATPGM-246 |
| 16 of 51 | 9 | 240-AIATPGMQI-248 |
| 17 of 51 | 9 | 243-TPGMQIRGF-251 |
| 18 of 51 | 9 | 271-LPVGGNEKK-279 |
| 19 of 51 | 9 | 274-GGNEKKAKL-282 |
| 20 of 51 | 9 | 275-GNEKKAKLA-283 |
| 21 of 51 | 9 | 277-EKKAKLANV-285 |
| 22 of 51 | 9 | 280-AKLANVVRK-288 |
| 23 of 51 | 9 | 281-KLANVVRKM-289 |
| 24 of 51 | 9 | 340-APIMFSNKM-348 |
| 25 of 51 | 9 | 342-IMFSNKMAR-350 |
| 26 of 51 | 9 | 343-MFSNKMARL-351 |
| 27 of 51 | 9 | 347-KMARLGKGY-355 |
| 28 of 51 | 9 | 349-ARLGKGYMF-357 |
| 29 of 51 | 9 | 403-LSPGMMMGM-411 |
| 30 of 51 | 9 | 404-SPGMMMGMF-412 |

| Table 1 | | |
|---|--------|-------------------|
| Peptide | Length | Sequence |
| 31 of 51 | 9 | 407-MMMGMFNML-415 |
| 32 of 51 | 9 | 410-GMFNMLSTV-418 |
| 33 of 51 | 9 | 411-MFNMLSTVL-419 |
| 34 of 51 | 9 | 413-NMLSTVLGV-421 |
| 35 of 51 | 9 | 439-DGLQSSDDF-447 |
| 36 of 51 | 9 | 441-LQSSDDFAL-449 |
| 37 of 51 | 9 | 443-SSDDFALIV-451 |
| 38 of 51 | 9 | 475-INMSKKKSY-483 |
| 39 of 51 | 9 | 487-TGTFEFTSF-495 |
| 40 of 51 | 9 | 489-TFEFTSFFY-497 |
| 41 of 51 | 9 | 491-EFTSFFYRY-499 |
| 42 of 51 | 9 | 497-YRYGFVANF-505 |
| 43 of 51 | 9 | 501-FVANFSMEL-509 |
| 44 of 51 | 9 | 504-NFSMELPSF-512 |
| 45 of 51 | 9 | 598-LYNIRNLHI-606 |
| 46 of 51 | 9 | 658-DAVATTHSW-666 |
| 47 of 51 | 9 | 669-KRNRSILNT-677 |
| 48 of 51 | 9 | 697-EKFFPSSSY-705 |
| 49 of 51 | 9 | 698-KFFPSSSYR-706 |
| 50 of 51 | 9 | 699-FFPSSSYRR-707 |
| 51 of 51 | 9 | 716-EAMVSRARI-724 |
| NRC-255: Influenza Virus A, PB2 Peptides | | |
| 1 of 30 | 9 | 23-TTVDHMAIL-31 |
| 2 of 30 | 9 | 24-TVDHMAIIK-32 |
| 3 of 30 | 9 | 26-DHMAIIKKY-34 |
| 4 of 30 | 9 | 30-IIKKYTSGR-38 |
| 5 of 30 | 9 | 33-KYTSGRQEK-41 |
| 6 of 30 | 9 | 45-LRMKWMMAM-53 |
| 7 of 30 | 9 | 47-MKWMMAMKY-55 |
| 8 of 30 | 9 | 49-WMMAMKYPI-57 |
| 9 of 30 | 9 | 158-EAQDVIMEV-166 |
| 10 of 30 | 9 | 160-QDVIMEVVF-168 |
| 11 of 30 | 9 | 204-AYMLERELV-212 |
| 12 of 30 | 9 | 205-YMLERELVR-213 |
| 13 of 30 | 9 | 206-MLERELVRK-214 |
| 14 of 30 | 9 | 208-ERELVRKTR-216 |
| 15 of 30 | 9 | 209-RELVKTRF-217 |
| 16 of 30 | 9 | 210-ELVRKTRFL-218 |
| 17 of 30 | 9 | 212-VRKTRFLPV-220 |
| 18 of 30 | 9 | 232-LHLTQGTCW-240 |
| 19 of 30 | 9 | 279-SLLEMCHST-287 |
| 20 of 30 | 9 | 320-SSFSFGGF-328 |
| 21 of 30 | 9 | 322-SFSFGGFTF-330 |
| 22 of 30 | 9 | 412-KAVRGDLNF-420 |

| Table 1 | | |
|----------|--------|-------------------|
| Peptide | Length | Sequence |
| 23 of 30 | 9 | 420-FVNRANQRL-428 |
| 24 of 30 | 9 | 423-RANQRLNPM-431 |
| 25 of 30 | 9 | 426-QRLNPMHQL-434 |
| 26 of 30 | 9 | 427-RLNPMHQLL-435 |
| 27 of 30 | 9 | 686-VESAVLRGF-694 |
| 28 of 30 | 9 | 742-SILTDSQTA-750 |
| 29 of 30 | 9 | 743-ILTDSQTAT-751 |
| 30 of 30 | 9 | 744-LTDSQTATK-752 |

| Table 2 | | |
|--|------------|---------------------------|
| Peptide | Solubility | Solvent |
| NRC-248: Influenza A Virus, M1 peptides | | |
| 1 of 21 | 1mg/mL | 50% acetonitrile in water |
| 2 of 21 | 1mg/mL | 50% acetonitrile in water |
| 3 of 21 | 1mg/mL | 50% acetonitrile in water |
| 4 of 21 | 1mg/mL | 50% acetonitrile in water |
| 5 of 21 | 1mg/mL | 50% acetonitrile in water |
| 6 of 21 | 1mg/mL | 50% acetonitrile in water |
| 7 of 21 | 1mg/mL | 100% DMSO |
| 8 of 21 | 1mg/mL | 50% acetonitrile in water |
| 9 of 21 | 1mg/mL | 50% acetonitrile in water |
| 10 of 21 | 1mg/mL | 50% acetonitrile in water |
| 11 of 21 | 1mg/mL | 50% acetonitrile in water |
| 12 of 21 | 1mg/mL | 50% acetonitrile in water |
| 13 of 21 | 1mg/mL | 50% acetonitrile in water |
| 14 of 21 | 1mg/mL | 50% acetonitrile in water |
| 15 of 21 | 1mg/mL | 50% acetonitrile in water |
| 16 of 21 | 1mg/mL | 50% acetonitrile in water |
| 17 of 21 | 1mg/mL | 50% acetonitrile in water |
| 18 of 21 | 1mg/mL | 50% acetonitrile in water |
| 19 of 21 | 1mg/mL | 50% acetonitrile in water |
| 20 of 21 | 1mg/mL | 50% acetonitrile in water |
| 21 of 21 | 1mg/mL | 50% acetonitrile in water |
| NRC-249: Influenza A Virus, M2 peptides | | |
| 1 of 5 | 1mg/mL | 50% acetonitrile in water |
| 2 of 5 | 1mg/mL | 50% acetonitrile in water |
| 3 of 5 | 1mg/mL | 50% acetonitrile in water |
| 4 of 5 | 1mg/mL | 50% acetonitrile in water |
| 5 of 5 | 1mg/mL | 50% acetonitrile in water |

| Table 2 | | |
|---|------------|---------------------------|
| Peptide | Solubility | Solvent |
| NRC-250: Influenza A Virus, NA peptides | | |
| 1 of 3 | 1mg/mL | 50% acetonitrile in water |
| 2 of 3 | 1mg/mL | 50% acetonitrile in water |
| 3 of 3 | 1mg/mL | 50% acetonitrile in water |
| NRC-251: Influenza A Virus, NP peptides | | |
| 1 of 19 | 1mg/mL | 50% acetonitrile in water |
| 2 of 19 | 1mg/mL | 50% acetonitrile in water |
| 3 of 19 | 1mg/mL | 50% acetonitrile in water |
| 4 of 19 | 1mg/mL | 50% acetonitrile in water |
| 5 of 19 | 1mg/mL | 50% acetonitrile in water |
| 6 of 19 | 1mg/mL | 50% acetonitrile in water |
| 7 of 19 | 1mg/mL | 50% acetonitrile in water |
| 8 of 19 | 1mg/mL | 50% acetonitrile in water |
| 9 of 19 | 1mg/mL | 50% acetonitrile in water |
| 10 of 19 | 1mg/mL | 50% acetonitrile in water |
| 11 of 19 | 1mg/mL | 50% acetonitrile in water |
| 12 of 19 | 1mg/mL | 50% acetonitrile in water |
| 13 of 19 | 1mg/mL | 50% acetonitrile in water |
| 14 of 19 | 1mg/mL | 50% acetonitrile in water |
| 15 of 19 | 1mg/mL | 50% acetonitrile in water |
| 16 of 19 | 1mg/mL | 50% acetonitrile in water |
| 17 of 19 | 1mg/mL | 50% acetonitrile in water |
| 18 of 19 | 1mg/mL | 50% acetonitrile in water |
| 19 of 19 | 1mg/mL | 50% acetonitrile in water |
| NRC-252: Influenza A Virus, NS2 peptides | | |
| 1 of 2 | 1mg/mL | 50% acetonitrile in water |
| 2 of 2 | 1mg/mL | 50% acetonitrile in water |
| NRC-253: Influenza A Virus, PA peptides | | |
| 1 of 28 | 1mg/mL | 50% acetonitrile in water |
| 2 of 28 | 1mg/mL | 50% acetonitrile in water |
| 3 of 28 | 1mg/mL | 50% acetonitrile in water |
| 4 of 28 | 1mg/mL | 50% acetonitrile in water |
| 5 of 28 | 1mg/mL | 50% acetonitrile in water |
| 6 of 28 | 1mg/mL | 50% acetonitrile in water |
| 7 of 28 | 1mg/mL | 50% acetonitrile in water |
| 8 of 28 | 1mg/mL | 50% acetonitrile in water |
| 9 of 28 | 1mg/mL | 50% acetonitrile in water |
| 10 of 28 | 1mg/mL | 50% acetonitrile in water |
| 11 of 28 | 1mg/mL | 50% acetonitrile in water |
| 12 of 28 | 1mg/mL | 50% acetonitrile in water |
| 13 of 28 | 1mg/mL | 50% acetonitrile in water |
| 14 of 28 | 1mg/mL | 50% acetonitrile in water |
| 15 of 28 | 1mg/mL | 50% acetonitrile in water |
| 16 of 28 | 1mg/mL | 50% acetonitrile in water |
| 17 of 28 | 1mg/mL | 50% acetonitrile in water |
| 18 of 28 | 1mg/mL | 50% acetonitrile in water |

| Table 2 | | |
|---|------------|---------------------------|
| Peptide | Solubility | Solvent |
| 19 of 28 | 1mg/mL | 50% acetonitrile in water |
| 20 of 28 | 1mg/mL | 50% acetonitrile in water |
| 21 of 28 | 1mg/mL | 50% acetonitrile in water |
| 22 of 28 | 1mg/mL | 50% acetonitrile in water |
| 23 of 28 | 1mg/mL | 50% acetonitrile in water |
| 24 of 28 | 1mg/mL | 50% acetonitrile in water |
| 25 of 28 | 1mg/mL | 50% acetonitrile in water |
| 26 of 28 | 1mg/mL | 50% acetonitrile in water |
| 27 of 28 | 1mg/mL | 50% acetonitrile in water |
| 28 of 28 | 1mg/mL | 50% acetonitrile in water |
| NRC-254: Influenza A Virus, PB1 peptides | | |
| 1 of 51 | 1mg/mL | 50% acetonitrile in water |
| 2 of 51 | 1mg/mL | 50% acetonitrile in water |
| 3 of 51 | 1mg/mL | 50% acetonitrile in water |
| 4 of 51 | 1mg/mL | 50% acetonitrile in water |
| 5 of 51 | 1mg/mL | 50% acetonitrile in water |
| 6 of 51 | 1mg/mL | 50% acetonitrile in water |
| 7 of 51 | 1mg/mL | 50% acetonitrile in water |
| 8 of 51 | 1mg/mL | 50% acetonitrile in water |
| 9 of 51 | 1mg/mL | 50% acetonitrile in water |
| 10 of 51 | 1mg/mL | 50% acetonitrile in water |
| 11 of 51 | 1mg/mL | 50% acetonitrile in water |
| 12 of 51 | 1mg/mL | 50% acetonitrile in water |
| 13 of 51 | 1mg/mL | 50% acetonitrile in water |
| 14 of 51 | 1mg/mL | 50% acetonitrile in water |
| 15 of 51 | 1mg/mL | 50% acetonitrile in water |
| 16 of 51 | 1mg/mL | 50% acetonitrile in water |
| 17 of 51 | 1mg/mL | 50% acetonitrile in water |
| 18 of 51 | 1mg/mL | 50% acetonitrile in water |
| 19 of 51 | 1mg/mL | 50% acetonitrile in water |
| 20 of 51 | 1mg/mL | 50% acetonitrile in water |
| 21 of 51 | 1mg/mL | 50% acetonitrile in water |
| 22 of 51 | 1mg/mL | 50% acetonitrile in water |
| 23 of 51 | 1mg/mL | 50% acetonitrile in water |
| 24 of 51 | 1mg/mL | 50% acetonitrile in water |
| 25 of 51 | 1mg/mL | 50% acetonitrile in water |
| 26 of 51 | 1mg/mL | 50% acetonitrile in water |
| 27 of 51 | 1mg/mL | 50% acetonitrile in water |
| 28 of 51 | 1mg/mL | 50% acetonitrile in water |
| 29 of 51 | 1mg/mL | 50% acetonitrile in water |
| 30 of 51 | 1mg/mL | 50% acetonitrile in water |
| 31 of 51 | 1mg/mL | 50% acetonitrile in water |
| 32 of 51 | 1mg/mL | 50% acetonitrile in water |
| 33 of 51 | 1mg/mL | 100% DMSO |
| 34 of 51 | 1mg/mL | 50% acetonitrile in water |

| Table 2 | | |
|---|------------|------------------------------------|
| Peptide | Solubility | Solvent |
| 35 of 51 | 1mg/mL | 50% acetonitrile in water |
| 36 of 51 | 1mg/mL | 50% acetonitrile in water |
| 37 of 51 | 1mg/mL | 50% acetonitrile in water |
| 38 of 51 | 1mg/mL | 50% acetonitrile in water |
| 39 of 51 | 1mg/mL | 50% acetonitrile in water |
| 40 of 51 | 1mg/mL | 50% acetonitrile in water |
| 41 of 51 | 1mg/mL | 50% acetonitrile in water |
| 42 of 51 | 1mg/mL | 50% acetonitrile in water |
| 43 of 51 | 1mg/mL | 50% acetonitrile in water |
| 44 of 51 | 1mg/mL | 50% acetonitrile in water |
| 45 of 51 | 1mg/mL | 50% acetonitrile in water |
| 46 of 51 | 1mg/mL | 50% acetonitrile in water |
| 47 of 51 | 1mg/mL | 50% acetonitrile in water |
| 48 of 51 | 1mg/mL | 50% acetonitrile in water |
| 49 of 51 | 1mg/mL | 50% acetonitrile in water |
| 50 of 51 | 1mg/mL | 50% acetonitrile in water |
| 51 of 51 | 1mg/mL | 50% acetonitrile in water |
| NRC-255: Influenza A Virus, PB2 peptides | | |
| 1 of 30 | 1mg/mL | 50% acetonitrile in water |
| 2 of 30 | 1mg/mL | 50% acetonitrile in water |
| 3 of 30 | 1mg/mL | 50% acetonitrile in water |
| 4 of 30 | 1mg/mL | 50% acetonitrile in water |
| 5 of 30 | 1mg/mL | 50% acetonitrile in water |
| 6 of 30 | 1mg/mL | 50% acetonitrile in water |
| 7 of 30 | 1mg/mL | 50% acetonitrile in water |
| 8 of 30 | 1mg/mL | 50% acetonitrile in water |
| 9 of 30 | 1mg/mL | 50% acetonitrile in water |
| 10 of 30 | 1mg/mL | ammonium hydroxide and water, pH 9 |
| 11 of 30 | 1mg/mL | 50% acetonitrile in water |
| 12 of 30 | 1mg/mL | 50% acetonitrile in water |
| 13 of 30 | 1mg/mL | 50% acetonitrile in water |
| 14 of 30 | 1mg/mL | 50% acetonitrile in water |
| 15 of 30 | 1mg/mL | 50% acetonitrile in water |
| 16 of 30 | 1mg/mL | 50% acetonitrile in water |
| 17 of 30 | 1mg/mL | 50% acetonitrile in water |
| 18 of 30 | 1mg/mL | 50% acetonitrile in water |
| 19 of 30 | 1mg/mL | 50% acetonitrile in water |
| 20 of 30 | 1mg/mL | 50% acetonitrile in water |
| 21 of 30 | 1mg/mL | 50% acetonitrile in water |
| 22 of 30 | 1mg/mL | 50% acetonitrile in water |
| 23 of 30 | 1mg/mL | 50% acetonitrile in water |
| 24 of 30 | 1mg/mL | 50% acetonitrile in water |
| 25 of 30 | 1mg/mL | 50% acetonitrile in water |
| 26 of 30 | 1mg/mL | 50% acetonitrile in water |

| Table 2 | | |
|----------|------------|---------------------------|
| Peptide | Solubility | Solvent |
| 27 of 30 | 1mg/mL | 50% acetonitrile in water |
| 28 of 30 | 1mg/mL | 50% acetonitrile in water |
| 29 of 30 | 1mg/mL | 50% acetonitrile in water |
| 30 of 30 | 1mg/mL | 50% acetonitrile in water |